Skip to main content
BioMed Research International logoLink to BioMed Research International
. 2016 Sep 6;2016:6068437. doi: 10.1155/2016/6068437

Network Based Approach in the Establishment of the Relationship between Type 2 Diabetes Mellitus and Its Complications at the Molecular Level Coupled with Molecular Docking Mechanism

Shailima Rampogu 1,*, Mary Rampogu Lemuel 2
PMCID: PMC5028860  PMID: 27699170

Abstract

Diabetes mellitus (DM) is one of the major metabolic disorders that is currently threatening the world. DM is seen associated with obesity and diabetic retinopathy (DR). In the present paper we tried to evaluate the relationship between the three aliments at the gene level and further performed the molecular docking to identify the common drug for all the three diseases. We have adopted several software programs such as Phenopedia, VennViewer, and CDOCKER to accomplish the objective. Our results revealed six genes that commonly associated and are involved in the signalling pathway. Furthermore, evaluation of common gene association from the selected set of genes projected the presence of SIRT1 in all the three aliments. Therefore, we targeted protein 4KXQ which was produced from the gene SIRT1 and challenged it with eight phytochemicals, adopting the CDOCKER. C1 compound has displayed highest -CDOCKER energy and -CDOCKER interaction energy of 43.6905 and 43.3953, respectively. Therefore, this compound is regarded as the most potential lead molecule.

1. Introduction

Globally, type 2 diabetes mellitus (T2DM) is one of the leading causes of death and it is estimated that over 70% of the population effected with T2DM are in the developing countries, China leading the world with 92.4 million [1, 2]. Once a patient is diagnosed with T2DM, lento develops the other diseases. It is generally noted that the T2DM patients are obese; however, the molecular association that exists between them is far from clear. Statistical data show an alarming figure, with 34% of the US adults being obese [3] and it may soon increase by 21% in another three decades [4]. It is well evidenced that obese men are more prone to develop T2DM than obese women at the ratio of 11.2 : 10. Nevertheless, it has to be noted that several patients with unrestrained weight again are not likely to develop T2DM, which warrants the need for understanding their relationship at the molecular level [3]. Another complication, which is seen associated with T2DM, is the diabetic retinopathy (DR) gradually causing visual impairment leading to blindness [5]. Recent reports evidently state the relationship between the BMI and DR [6]. Generally, BMI is considered as a determinant factor for obesity [7]. Wei et al. [8] also reported association between them at the genetic level. It is, hence, extremely essential to identify the relationship that exists between all the three diseases, majorly focusing on which disease is the initiator of the other two, and further to identify a common drug that could be a potential lead for all the diseases. To achieve this we have depended upon the system biology, which gives freedom in evaluating the biological system at the gene level. Additionally, this paper also makes an effort to identify the common genes and protein involved with the three aliments.

The objective of the present paper is to identify the genes representing the individual diseases and, further, the common genes involved and later to perform molecular docking to determine an effective drug molecule.

2. Materials and Methods

2.1. Identification of the Common Genes

To identify the common genes, we have employed Phenopedia [9], Public Healthy Genomics Knowledge Base (V1.0), to search for the genes responsible of the diseases and, consequently, the genes responsible for the three aliments were identified. Later, they were imported onto the pathway linkers [10] to understand the significant common genes associated with all the three diseases, which are precisely involved in the signalling pathways.

Furthermore, in order to understand the disease-gene relationship, we relied on VennViewer, provided with the Comparative Toxicogenomics Databases, which has an ability to develop the Venn diagrams pertaining to three genes, diseases, or chemicals. For the present investigation, we worked with three diseases.

2.2. Protein Ligand Docking

In order to identify the candidate drug molecules, it is very essential to perform the protein ligand docking, modelling technique used to predict the orientation, and the position of the ligand upon docking. For the present investigation, the CDOCKER, available on the Discovery Studio, was adopted. CDOCKER specifically employs the CHARMm-based molecular dynamics method and further generates conformation adopting the high temperature and is then forwarded onto the binding site for binding pose analysis.

2.3. Protein Selection and Preparation

The protein selection for the present investigation is one of the most crucial aspects. Since we aim at identifying the protein from the common gene, we relied upon 4KXQ, a protein produced from the gene SIRT1 with the resolution of 1.85 Å and is known as NAD-dependent protein deacetylase which envisages developing a common drug for all the three diseases.

The selected protein was prepared prior to the docking studies by correcting the chemistry of the missing hydrogens and the unfilled valence atoms. Thereafter, the protein was subjected to energy minimization by applying the CHARMm force field until a satisfactory gradient tolerance was obtained.

2.4. Ligand Preparation

A total of eight natural compounds were chosen to challenge against the protein target molecule. These compounds were drawn on Marvin Sketch and their corresponding 3D structures were generated on the DS. CHARMm force field was applied as a measure to minimize the ligand molecules. The importance of choosing the natural compounds is to further formulate and translate them into nutraceuticals, Table 1.

Table 1.

Ligand name and structure.

Ligand name Structure
C1 graphic file with name BMRI2016-6068437.tab1.i001.jpg

C2 graphic file with name BMRI2016-6068437.tab1.i002.jpg

C3 graphic file with name BMRI2016-6068437.tab1.i003.jpg

C4 graphic file with name BMRI2016-6068437.tab1.i004.jpg

C5 graphic file with name BMRI2016-6068437.tab1.i005.jpg

C6 graphic file with name BMRI2016-6068437.tab1.i006.jpg

C7 graphic file with name BMRI2016-6068437.tab1.i007.jpg

C8 graphic file with name BMRI2016-6068437.tab1.i008.jpg

3. Results and Discussions

3.1. Identification of the Common Genes

Phenopedia was employed to identify the genes associated with obesity, diabetes mellitus, and diabetic retinopathy, respectively. A systematic search was conducted providing the disease names as a query. Consequently, SIRT1, MC4R, and VEGFA were determined for diabetes mellitus, type 2, obesity, and diabetic retinopathy, respectively.

Later, they were assessed for the common genes on pathway linkers that have an ability to link proteins to the signalling pathways. A total of 48 proteins were found to be associated; nevertheless, only six proteins were seen interacting with all the three genes. In addition, all the six proteins were involved in the signalling pathways and the nonsignalling proteins were ignored, Figure 1.

Figure 1.

Figure 1

Red nodes indicate the query proteins and the proteins present in the dotted circles, VTN, PRKACA, RELA, EP300, AKT1, EIF2C1, are the common proteins associated with the query proteins. Dark grey nodes represent the signalling pathway members and the light grey nodes represent the nonsignalling pathway members.

Alternatively, we tried to evaluate the gene that is involved in all the three disorders and in this pursuit, we adopted the VennViewer [11] available on Comparative Toxicogenomics Database (CTD) facilitating the three genes of interest as inputs. Following which, the results were generated pronouncing SIRT1 to be involved with all the three diseases, Figure 2. Additionally, we have identified two other genes, ICAM1 and SOD1, that were seen involved with the three diseases.

Figure 2.

Figure 2

VennViewer diagram displaying the common genes associated with the three diseases.

3.2. Active Site Identification

Active site was identified based upon the cocrystal and all the amino acids around the cocrystals were taken into consideration. Furthermore, the cocrystal docking was performed to ascertain the active site and an acceptable RMSD of 0.9 was obtained projecting that our docking parameters are valid ones, Figure 3.

Figure 3.

Figure 3

Docking of the cocrystal represented in magenta. Blue indicates the docked pose.

3.3. Molecular Docking Mechanism

Molecular docking was performed adopting the CDOCKER, which depends on CHARMm-based force field. Subsequently, diverse poses are generated adopting the random rigid body rotation and simulate annealing. In order to initiate this mechanism, all the default parameters were considered allowing the generation of 10 poses for every ligand. The docking estimation was performed by the -CDOCKER energy, which was calculated, based upon the internal ligand strain energy and receptor-ligand interaction energy. Additionally, -CDOCKER interaction signifies the energy of the nonbonded interaction that exists between the protein and the ligand. In both the cases, it has to be noted that greater -CDOCKER energy and -CDOCKER interaction energy value implies greater favourable binding between the protein and the ligand.

As mentioned above, eight naturally available phytochemicals were challenged with the protein target. Seven ligands have displayed an efficient docking with the generation of 10 conformers each; however, one ligand failed to dock. The representative dock results are displayed in Table 2. Among the docked ligands, C1 displayed higher -CDOCKER energy and -CDOCKER interaction energy value-making itself the potential leading molecule for the three common diseases. Furthermore, the protein ligand complex was assessed for the hydrogen bond interaction followed by the binding mode analysis. Delineating on the interactions reveals that the residues, ASN465, SER442, and ARG274, have participated in the hydrogen bond formation, Figure 4, while the amino acid ARG466 participated by Vander Walls interaction and ASP272 and GLU467 interacted by the Pi-anion and ARG274 with Pi-alkyl bonds, respectively, Figure 5. Regardless of the binding energies projected by the ligands, they all obeyed the same pattern of binding mode as with the cocrystal.

Table 2.

CDOCKER scores.

Compound name -CDOCKER energy -CDOCKER interaction
C1 43.6905 46.3953
C2 43.594 46.2159
C3 43.4827 46.2751
C4 41.0953 43.8479
C5 39.5149 45.9837
C6 38.0443 41.3656
C7 37.9135 41.3597
C8 37.8987 41.12
C9 37.8849 41.0074
C10 36.7593 44.0819
C11 34.1467 30.8196
C12 34.0604 30.898
C13 33.9507 30.5325
C14 33.8314 30.5452
C15 33.7333 30.2313
C16 33.6998 30.4529
C17 33.6256 30.2404
C18 33.3807 29.9087
C19 33.3558 29.9264
C20 33.3249 29.8632
C21 16.1116 43.6807
C22 15.345 45.089
C23 13.6468 43.0185
C24 11.3323 33.3176
C25 11.117 29.8403
C26 10.8676 39.7459
C27 10.6943 36.1858
C28 6.76306 39.212
C29 6.74011 29.1499
C30 6.5533 28.9768
C31 6.37705 26.9035
C32 6.2874 27.1806
C33 6.10317 27.0072
C34 5.97667 26.6726
C35 5.92624 27.6206
C36 5.92438 26.961
C37 5.85956 26.796
C38 5.85111 26.9232
C39 5.82535 30.565
C40 5.72081 26.7008
C41 5.42032 42.1491
C42 5.2531 32.1618
C43 4.22422 40.4729
C44 3.15406 40.3832
C45 2.38138 36.5095
C46 2.31672 38.5722
C47 2.27477 36.9574
C48 1.9534 36.4364
C49 1.49815 36.2616
C50 1.18856 38.0515
C51 0.420181 22.2711
C52 0.183442 23.049
C53 0.0514005 48.6528
C54 −1.0173 26.8177
C55 −1.88654 45.5105
C56 −2.08119 47.3119
C57 −2.33309 48.7866
C58 −2.40939 41.621
C59 −3.58299 42.0705
C60 −4.44257 41.6539
C61 −4.72479 41.9058
C62 −4.92736 45.634
C63 −5.16567 44.7624
C64 −6.0176 39.6754
C65 −6.11149 39.7136
C66 −7.27294 42.9186
C67 −13.8456 32.8447
C68 −16.8805 32.324
C69 −19.8347 37.0598
C70 −19.8904 32.4273

Figure 4.

Figure 4

Protein ligand docking. Green dashed lines represent the hydrogen bond interactions.

Figure 5.

Figure 5

2D representation of the protein ligand interaction. Brown dotted lines indicate the pi-anion bonds, pink dotted lines denote the pi-alkyl bonds, and the light green dotted lines represent the van der Waals interactions.

4. Discussion

It has been a long subject of debate regarding the diabetes mellitus type 2 and its associated complication [12]. However, nothing concrete has yet been established. In the present paper, we have successfully evaluated the common genes associated with the three diseases. These findings could lead the researchers towards unfolding the mystery behind the diabetes complications. In the event of identifying the common genes associated among the three selected genes, our results determine SIRT1 to be the link gene, a gene which was chosen for diabetes mellitus. Therefore, it can be deduced that diabetes mellitus can influence the manifestation of obesity and diabetic retinopathy. Furthermore, our study centralizes on the identification of a common nutraceutical for all the three aliments. Accordingly, we have preferred the protein 4KXQ, a protein produced from the gene SIRT1. We have further evidenced the presence of SIRT1 in DM, obesity, and DR [1315]. Following this, we challenged the selected protein with eight natural compounds or the phytochemicals. Natural compounds offer a host of applications such as low cost, wider availability, and low side effects which are a few to mention. Additionally, they can be supplemented through diet. Amongst all the ligand molecules, C1 emerged as the best ligand demonstrating a highest -CDOCKER interaction value of 46.3953 and its corresponding -CDOCKER energy of 43.6905, respectively.

In summary, our results signify being of greater scientific usefulness in finding the most prominent results in combating the diabetes complications.

Competing Interests

The authors declare that they have no competing interests.

References

  • 1.Rawal L. B., Tapp R. J., Williams E. D., Chan C., Yasin S., Oldenburg B. Prevention of type 2 diabetes and its complications in developing countries: a review. International Journal of Behavioral Medicine. 2012;19(2):121–133. doi: 10.1007/s12529-011-9162-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Yang W., Lu J., Weng J., et al. Prevalence of diabetes among men and women in China. The New England Journal of Medicine. 2010;362(12):1090–1101. doi: 10.1056/NEJMoa0908292. [DOI] [PubMed] [Google Scholar]
  • 3.Eckel R. H., Kahn S. E., Ferrannini E., et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care. 2011;34(6):1424–1430. doi: 10.2337/dc11-0447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Boyle J. P., Thompson T. J., Gregg E. W., Barker L. E., Williamson D. F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics. 2010;8(1, article 29) doi: 10.1186/1478-7954-8-29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Swetha V., Jeganathan E. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care. 2008;31(9):1905–1912. doi: 10.2337/dc08-0342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kaštelan S., Tomić M., Gverović Antunica A., Ljubić S., Salopek Rabatić J., Karabatić M. Body mass index: a risk factor for retinopathy in type 2 diabetic patients. Mediators of Inflammation. 2013;2013:8. doi: 10.1155/2013/436329.436329 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Raman R., Rani P. K., Gnanamoorthy P., Sudhir R. R., Kumaramanikavel G., Sharma T. Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics study (SN-DREAMS Report no. 8) Acta Diabetologica. 2010;47(3):209–215. doi: 10.1007/s00592-009-0113-8. [DOI] [PubMed] [Google Scholar]
  • 8.Wei F., Cai C., Feng S., et al. TOX and CDKN2A/B gene polymorphisms are associated with type 2 diabetes in Han Chinese. Scientific Reports. 2015;5 doi: 10.1038/srep11900.11900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Yu W., Clyne M., Khoury M. J., Gwinn M. Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics. 2010;26(1):145–146. doi: 10.1093/bioinformatics/btp618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Farkas I. J., Szántó-Várnagy Á., Korcsmáros T. Linking proteins to signaling pathways for experiment design and evaluation. PLoS ONE. 2012;7(4) doi: 10.1371/journal.pone.0036202.e36202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Grondin C. J., Davis A. P., Wiegers T. C., et al. Advancing exposure science through chemical data curation and integration in the comparative toxicogenomics database. Environmental Health Perspectives. 2016 doi: 10.1289/ehp174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rosenstock J. Reflecting on type 2 diabetes prevention: more questions than answers! Diabetes, Obesity and Metabolism. 2007;9(1):3–11. doi: 10.1111/j.1463-1326.2007.00768.x. [DOI] [PubMed] [Google Scholar]
  • 13.Kitada M., Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes and Metabolism Journal. 2013;37(5):315–325. doi: 10.4093/dmj.2013.37.5.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zillikens M. C., Van Meurs J. B. J., Rivadeneira F., et al. SIRT1 genetic variation is related to BMI and risk of obesity. Diabetes. 2009;58(12):2828–2834. doi: 10.2337/db09-0536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Liu S., Lin Y. U., Liu X. Protective effects of SIRT1 in patients with proliferative diabetic retinopathy via the inhibition of IL-17 expression. Experimental and Therapeutic Medicine. 2016;11(1):257–262. doi: 10.3892/etm.2015.2877. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BioMed Research International are provided here courtesy of Wiley

RESOURCES